Cross-Sector entity
Of the tracked stories, 12 of 18 also mention Wall Street Zen, the most common co-covered peer. Across a 187-day span, the pace is roughly 0.7 stories per week. The busiest single day carried 5. The clearest coverage concentration is markets: 6 of 18 stories, with the rest divided among 7 other categories.
18 verified stories tracked
Last mentioned: 15h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 12 of 18 also mention Wall Street Zen, the most common co-covered peer. Across a 187-day span, the pace is roughly 0.7 stories per week. The busiest single day carried 5. The clearest coverage concentration is markets: 6 of 18 stories, with the rest divided among 7 other categories. This profile follows 18 Cross-Sector stories mentioning MarketBeat.com across the period from February 19, 2026 to August 24, 2026. 0% of these stories carry negative sentiment. The tracked stories average 2.1 original sources each.
Computed from the 18 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MarketBeat.com. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen upgrades both stocks to Hold
Wall Street Zen upgraded CTNM and ENVB from Sell to Hold in Sunday research notes.
Wall Street Zen upgrades both stocks
Wall Street Zen raised AMPY from strong sell to hold and BRSP from sell to hold.
Quarterly earnings release
Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
Friday trading close
AMPY opened at $4.78 and BRSP opened at $5.00.
Enveric reports quarterly loss
Enveric Biosciences reported EPS of -$0.76 for the quarter.
Q2 earnings released; EPS beats consensus
Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
Benchmark and Weiss update AMPY
Benchmark cut the AMPY target to $9.00 from $11.00 with a buy rating; Weiss raised AMPY from sell(d) to sell(d+).
Wall Street Zen downgrades to Hold
Wall Street Zen cut both Klaviyo and Oceaneering International from Buy to Hold in Saturday research notes.
Citigroup lifts KVYO target
Citigroup raised its Klaviyo price target from $34.00 to $36.00 with a Buy rating.
KVYO analyst revisions
Stephens, BTIG, Stifel, and Truist adjusted price targets on Klaviyo following earnings.
Klaviyo Q2 earnings
Klaviyo reported EPS of $0.19, meeting consensus, and revenue of $370.58 million.
RBC raises CTNM target to $23
Royal Bank of Canada raised its Contineum target from $22.00 to $23.00 with an Outperform rating.
OII insider sale
SVP Christopher J. Dyer sold 1,200 OII shares at an average price of $47.65 for $57,180.
B. Riley trims BRSP target
B. Riley Financial lowered its BrightSpire Capital target from $7.00 to $6.50 with a buy rating.
Contineum reports Q2 results
Contineum reported Q2 EPS of -$0.40, beating consensus by $0.05.
Weiss Ratings upgrade
Weiss Ratings upgraded Lantern Pharma from 'sell (e+)' to 'sell (d-)'.
JonesTrading reiterates BRSP buy
JonesTrading reissued a buy rating and a $6.50 price objective on BrightSpire Capital.
Weiss upgrades OII
Weiss Ratings raised OII from Buy (B-) to Buy (B).
Barclays lifts OII target
Barclays increased its OII price objective from $39.00 to $47.00 with an Equal Weight rating.
Weiss Ratings reiterates Sell
Restated a 'sell (e+)' rating on MBRX shares in a research note
A Sunday analyst action shifted two healthcare microcaps from Sell to Hold. CTNM carries a $646.69M valuation and a $20.25 consensus target, while ENVB trades at $1.43 with a $6.41M market cap and negative P/E.
A rare double upgrade by Wall Street Zen moved Contineum Therapeutics and Enveric Biosciences from Sell to Hold, offering a momentary reprieve for two money-losing clinical-stage biotechs. CTNM trades near its 52-week high at $17.19 with a $20.25 consensus target, while ENVB's psychedelic pipeline carries a $6.41M market cap against a former $17.64 high.
Source: themarketsdaily.com · tickerreport.com
Wall Street Zen lifted Amplify Energy to Hold from Strong Sell on August 16, with shares at $4.78 and a $9 consensus target. Thin coverage and insider buying make the upgrade a key sentiment shift for a $198 million small-cap energy name.
Source: dailypolitical.com · tickerreport.com
Analysts remain mostly bullish on RTX and GE Vernova after July earnings, lifting price targets to as high as $250 and $1,338 respectively. Friday's gains came on unusually light volume, raising questions about conviction. Finance readers get a breakdown of target upside, valuation, and risk metrics.
Source: tickerreport.com · dailypolitical.com
A MarketBeat-based comparison shows ZOOZ Power offers 85.01% implied upside versus Regal Rexnord's 39.62%, but the ownership and volatility profiles point in opposite directions. Regal Rexnord wins on 9 of 12 factors, yet ZOOZ's insider-heavy ownership and analyst target suggest a higher-reward, lower-liquidity opportunity.
Source: Ticker Report · Watch List News
Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Source: dailypolitical.com · themarketsdaily.com
Lantern Pharma's quarterly EPS miss of $0.19 highlights the cash-intensive nature of AI-powered oncology drug discovery. The clinical-stage company has no product revenue, and its stock trades well below moving averages. Healthcare executives should monitor its platform and funding runway rather than quarterly losses.
Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Source: dailypolitical.com · themarketsdaily.com
Single-family rental REIT American Homes 4 Rent has a modestly reduced $38 price target from Morgan Stanley, still above a $36.78 consensus and leaving 11% upside. The maintained Overweight rating reinforces the resilience of the SFR asset class amid housing supply constraints.
Morgan Stanley trimmed its American Homes 4 Rent target to $38 from $38.50 while keeping an Overweight rating, against a $36.78 consensus and Moderate Buy average. Equity research actions from Jefferies, UBS, RBC, Mizuho, and Compass Point reveal a broadly constructive but price-sensitive stance on the REIT.
Source: themarketsdaily.com · tickerreport.com
SaaS and cloud operators are watching Klaviyo as a high-multiple vertical SaaS proxy. Wall Street Zen's Buy-to-Hold cut, after Q2 revenue of $370.58 million and EPS in line, shows how quickly a premium valuation can compress when growth doesn't exceed expectations.
Marketing and AdTech teams relying on Klaviyo face new investor scrutiny after Wall Street Zen cut the stock to Hold despite Q2 revenue of $370.58 million and in-line EPS of $0.19. The downgrade lands as analyst targets diverge while the company trades at a 895.95 P/E, raising questions about martech spending sustainability.
Wall Street Zen downgraded both Oceaneering International and Klaviyo from Buy to Hold, spotlighting two $5 billion market-cap companies with vastly different P/E ratios—14.59 for OII and 895.95 for KVYO. The ratings actions come as consensus targets diverge from current prices.
Source: dailypolitical.com · themarketsdaily.com
This review offers healthcare strategists a snapshot of two small-cap suppliers: NexGel's insider-heavy ownership and stronger profitability versus Bluejay's institutionally backed diagnostic platform.
A MarketBeat comparison finds NexGel beats Bluejay Diagnostics on 9 of 13 metrics, with a $2.00 target and 284.69% upside. The biotech lens highlights divergent risk profiles between a diagnostics platform and a biomaterials company.
Source: tickerreport.com · dailypolitical.com
Rivian Automotive is facing increased scrutiny as DA Davidson and Wall Street Zen both downgraded the EV maker's stock, citing valuation and performance risks. While Benchmark remains a bullish outlier, the consensus reflects growing caution regarding Rivian's path to profitability in a cooling market.
Source: Daily Political · Defenseworld Net
